Skip to Content
Morningstar

Bayer AG ADR BAYRY Stock Quote

Morningstar Rating
| Rating as of

PINX:BAYRY

Morningstar‘s Stock Analysis BAYRY

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Investor
Is it the right time to buy or sell?
Find out with Morningstar Investor

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

Capital Allocation

INVESTOR

Undervalued Bayer Posts Strong 3Q, Buoyed by Strong Crop Science Pricing and Recent Drug Launches

Damien Conover, CFA Sector Director

Analyst Note

| Damien Conover, CFA |

Bayer reported strong third-quarter results ahead of our expectations, but we don’t expect any major changes to our fair value estimate. Strong crop science prices partly supported the outperformance, but we expect increased competition in 2023, which will likely reverse some of Bayer's recent gains. However, the crop science business remains well positioned for growth over the long term, led by innovative new products (such as short-stature corn and next-generation trait protection) that help reinforce the firm’s wide moat.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics BAYRY

More

Company Profile BAYRY

Business Description

Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs as well as vitamins. The firm has a crop science business that includes seeds, pesticides, herbicides, and fungicides, which was expanded through the acquisition of Monsanto.

Contact
Kaiser-Wilhelm-Allee 1
Leverkusen, 51368, Germany
T +49 214301
Sector Healthcare
Industry Drug Manufacturers - General
Most Recent Earnings Jun 30, 2022
Fiscal Year End Dec 31, 2022
Employees 100,753

Related News BAYRY

Our Picks

10 Stocks for a Recession

These undervalued stocks come from high-quality companies in defensive sectors.
Susan Dziubinski
Stock Analyst Update

Bayer Posts Solid Q1 as Drug Pipeline Advances

We believe the favorable pricing driving the strong performance in the quarter will fade later in the year.
Damien Conover
Our Picks

13 Good Companies Run by Poor Capital Allocators

These firms all have wide and narrow economic moats but earn poor capital allocation ratings.
Susan Dziubinski
Stock Strategist Industry Reports

Big Biopharma Capital Allocation Supports Undervalued Stocks and Dividend Growth

Our top two picks in this wide-moat industry are poised to benefit.
Damien Conover
ETF Specialist

3 Things About ESG Investing We Can All Agree On

ESG doesn't have to be a divisive topic.
Ben Johnson
Market Update

7 Wide-Moat Stocks in Healthcare to Buy

We think the market is over-reacting to new drug pricing proposals, creating a buying opportunity.
Jakir Hossain
Stock Analyst Update

Bayer’s Announced Acquisition Adds Needed Boost

The wide-moat drug manufacture plans to acquire Asklepios BioPharmaceuticals.
Damien Conover
Stock Analyst Update

Drug Pricing Executive Orders Not Likely to Affect FVEs

We don’t expect these actions by President Trump to significantly affect our fair value estimates or moat ratings due to limited details, challenging implementation, and only minor impacts.
Damien Conover
Stock Analyst Update

Bayer Settlement Leads to Fair Value Estimate Decrease

While the costs will deplete capital, we don’t expect the settlement to create a major drag on the firm’s wide moat.
Damien Conover
Stock Strategist Industry Reports

Coronavirus Has Limited Impact on Big Pharma and Big Biotech

Moats, valuations, and dividends look attractive in the market pullback.
Damien Conover
Investing Specialists

It's Time to Look at Tax-Loss Selling

There's no telling if stocks have bottomed, but selling losing positions can help you find a silver lining in a down market.
Christine Benz
US Videos

A Close Look at Pharma Firms With an ESG Lens

An ESG frame helps us bring a better look at valuation within the healthcare sector.
Damien Conover
Stock Strategist Industry Reports

How ESG Risk Affects Pharma and Biotech Moats and Valuations

Morningstar and Sustainalytics offer complementary methodologies.
Karen Andersen
Stock Strategist Industry Reports

Rounding Up Big Pharma Earnings

Recent results from some of the most undervalued large drugmakers we cover.
Damien Conover
Stock Strategist

Market Too Focused on Corteva's Near Term

We see long-term potential for this wide-moat seed and chemical producer.
Seth Goldstein
US Videos

What to Expect From Big Pharma's Earnings

We expect solid results but will be listening for what a reduction in rebating means for sales growth at various firms, among other trends.
Damien Conover
Stock Strategist

We See Steady Growth for Bayer

Even with the recent glyphosate loss, scientific studies still support the product.
Damien Conover
Our Picks

30 Undervalued Stocks

Here are some of our analysts' best ideas across sectors.
Susan Dziubinski
Quarter-End Insights

Healthcare: Stock-Picking Increasingly Important

Drug manufacturers and healthcare providers offer the most upside.
Damien Conover
Quarter-End Insights

Healthcare: Specter of ACA Repeal Hangs Over Fairly Valued Sector

We expect appeals to delay any impact but revoking the ACA would likely create the most pressure for the healthcare services companies.
Damien Conover